In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
about
Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsRole of interleukin-12 in primary influenza virus infectionRole of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infectionEssential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression.Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in miceInterleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosisEffects of exogenous, nonleukemogenic, ecotropic murine leukemia virus infections on the immune systems of adult C57BL/6 miceAlpha/beta interferons increase host resistance to murine AIDS.Control of immunodeficiency and lymphoproliferation in mouse AIDS: studies of mice deficient in CD8+ T cells or perforinInterleukin-12 inhibits hepatitis B virus replication in transgenic mice.Modulation of murine AIDS-related pathology by concurrent antibody treatment and coinfection with Leishmania majorIL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.Induction of murine acquired immunodeficiency syndrome (MAIDS) in allophenic mice generated from strains susceptible and resistant to disease.Lung transplantation: infection, inflammation, and the microbiome.Current investigational drugs in psoriasis.Golgi phosphoprotein 2 in physiology and in diseases.IL-12 is produced by antigen-presenting cells stimulated with soluble alphabeta TCR and restores impaired T(h)1 responses.Interleukin-12 in infectious diseases.Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.Immune-based therapies for treatment of HIV infection.Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis.Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients.The role of MHC haplotypes H2d/H2b in mouse resistance/susceptibility to cyst formation is influenced by the lineage of infective Toxoplasma gondii strain.A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.Interleukin-12 and infectious diseases: a potential novel therapy.Relationship of cytokines and cytokine signaling to immunodeficiency disorders in the mouse.Mice transgenic for a soluble form of murine cytotoxic T lymphocyte antigen 4 are refractory to murine acquired immune deficiency sydrome development
P2860
Q28068375-284C3990-52A2-492A-9FE7-2F9405EFE3D2Q33784078-3DBB4A29-7B80-42C4-9077-9E46F2F4CD47Q33835324-468E3B3E-DBCE-4299-8670-8D4F90F0F180Q34327211-8ECBE1F4-7E2D-4167-AFD7-265E2B3601E3Q34969705-C2E6BAC1-2F4D-4FAB-963F-2F31622C3C9DQ35503716-5039F492-531D-44A2-ACA0-EF79697C1574Q35841216-10E3AFF7-ECB7-4FB2-A523-29CA6788F1ADQ35864222-092C82F9-60A8-4A80-A121-DE4B68EB0D49Q35877782-F9F4686D-8917-4FB6-BBAB-5B271F615E9BQ35881471-969D9B09-E4CD-4B21-A4B4-57A1E3C414B3Q35883083-94B66154-781E-4215-982B-54C15F472865Q35950374-B1DE0496-3653-4240-9B42-1E021DC8F713Q36376855-88761827-61E1-4801-8E34-CD4DF0C5C32DQ36377433-633EE153-24E6-479B-B320-3D0712F271E4Q37832677-AE2DDBED-9D50-4D21-977D-5A1AAD0386A8Q37991748-7984BB6C-97C5-4F59-8A0F-A0CC31065B25Q38041690-25030B57-44FE-4D60-9569-DDC5E004E393Q38498399-C42DF3FC-CBFA-4E27-9187-726494C5B9CDQ39820841-7C7442AC-72E5-4E90-B92A-1B53AA33626BQ40042449-56F34DEB-4856-4FDB-B00E-350699001CD3Q40959127-78BC7DD8-52E0-4549-BD27-3A51B158C0AAQ41428177-3BDF1F84-5381-4132-9335-0C991F787689Q42114649-9921624E-B550-44A6-9DA7-B5AAF3E896C2Q43698054-46EEC594-636B-4034-9986-8A6C33917BF6Q44988872-AC143811-5183-4D77-8E1E-AB43B8739B2FQ47619814-0D6A08AB-4D5A-432F-A7E9-FD337E79DE15Q47758487-67A46F56-DCF4-4316-BE7E-330E59DE4047Q56906521-4ABF0299-844C-42C8-BB61-3D2E6D17E0A2
P2860
In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@ast
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@en
type
label
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@ast
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@en
prefLabel
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@ast
In vivo treatment with interle ...... nodeficiency syndrome (MAIDS).
@en
P2860
P356
P1476
In vivo treatment with interle ...... unodeficiency syndrome (MAIDS)
@en
P2093
P2860
P304
P356
10.1084/JEM.180.6.2199
P407
P577
1994-12-01T00:00:00Z